

REGULATORY AFFAIRS

SPEAKER

 $BARCELONA - 13^{+h}MARCH 2019$




Background



Galenicum Health: is a pharmaceutical company focused in the development of generic products, with a B2B & B2C business model.

AGATE ROMAN - REGULATORY AFFAIRS B2B MANAGER

- Graduated in Pharmacy by the Universidad del País Vasco (UPV)
- Master Degree in Pharmaceutical Industry CESIF, BARCELONA
- I am a regulatory affairs senior specialist with more than 12 years experience specialised mainly in Regulatory Affairs.
- Experiencia in Human medicinal products, veterinarian and medical devices.




Why

One day in office

What is the market looking for

Are you the person?


Career Development



1. Why?

• Healthcare industries regulation has stemmed from avoiding the repetition of disasters







Elixir Sufanilamide 1937 US Antibiotic Prepared with diethylene glycol caused >100 deaths. Food, Drug & Cosmetic Art Regulation in 1938 requiring animal safety test & pre-approval of FDA 1957-1962 DE (EU, Australia, US, Canada) OTC 1960 DE Antiemetic for pregnant woman. Caused > 10,000 birth deformities cases. Tougher rules for the testing and licensing of drugs were applied in all countries

© 2019 | GALENICUM GROUP | CONFIDENTIAL | 13/03/2019

1. Why?. RA Functions


 Regulatory Affairs is involved in the development of new medicinal products from early on, by interpreting legal requirements and integrating regulatory principles, leading to prepare and submit the relevant regulatory dossiers to health authorities



The interface between the pharmaceutical company and the regulatory agencies across the world.

1. Why?. Registration procedure

All medicinal products require prior authorization to be marketed, and for that require a registration, which documents and assures it's quality, safety and efficacy




1. Why?. Marketing Authorisation (MA)

- A license to sell a medicine
- License granted by "Competent Authorities"
- Assessment is benefit/risk based on:
 - Quality
 - Safety
 - Efficacy

1. Why?. Registration Dossier: Common Technical Document (CTD)

• Common Technical Document (CTD) format in US, EU & JAPAN since July 2003



1. Why?. Registration Dossier: Structure

• Structure of the **Registration Dossier**: Module 3 Quality

CTD	EU CTD (NTA, Vol. 2B, Edition 2001)			
3.1	MODULE 3 TABLE OF CONTENTS			
3.2	BODY OF DATA			
3.2.S	DRUG SUBSTANCE			
3.2.S.1	General Information			
3.2.S.1.1	Nomenclature			
3.2.S.1.2	Structure			
3.2.S.1.3	General Properties			
3.2.S.2	Manufacture			
3.2.S.2.1	Manufacturer(s)			
3.2.8.2.2	Description of manufacturing process and process controls			
3.2.S.2.3	Control of materials			
3.2.S.2.4	Controls of critical steps and intermediates			
3.2.S.2.5	Process validation and/or evaluation			
3.2.S.2.6	Manufacturing process development			
3.2.S.3	Characterisation			
3.2.S.3.1	Elucidation of structure and other characteristics			
3.2.S.3.2	Impurities			
3.2.S.4	Control of drug substance			
3.2.S.4.1	Specification			
3.2.S.4.2	Analytical Procedures			

A. DRUG SUBSTANCE				
3.2.S.4.3	Validation of analytical procedures			
3.2.S.4.4	Batch analyses			
3.2.8.4.5	Justification of Specification			
3.2.5.5	Reference Standards or Materials			
3.2.S.6	Container Closure System			
3.2.S.7	Stability			



© 2019 | GALENICUM GROUP | CONFIDENTIAL | 13/03/2019

1. Why?. Registration Dossier: Structure

• Structure of the **Registration Dossier**: Module 3 Quality

3.2.P	DRUG PRODUCT				
3.2.P.1	Description and composition of the drug product				
3.2.P.2	Pharmaceutical Development				
3.2.P.2.4	Controls and critical steps and intermediates				
3.2.P.3	Manufacture				
3.2.P.3.1	Manufacturer(s)				
3.2.P.3.2	Batch formula				
3.2.P.3.3	Description of Manufacturing Process and Process Controls				
3.2.P.3.4	Controls of critical steps and intermediates				
3.2.P.3.5	Process validation and / or evaluation				
3.2.P.4	Control of excipients				
3.2.P.4.1	Specifications				
3.2.P.4.2	Analytical procedures				
3.2.P.4.3	Validation of analytical procedures				
3.2.P.4.4	Justification of specifications				
3.2.P.4.5	Excipients of human or animal origin				
3.2.P.4.6	Novel Excipients (ref to A 3)				

	A. DRUG PRODUCT				
3.2.P.5	Control of drug product				
3.2.P.5.1	Specification(s)				
3.2.P.5.2	Analytical Procedures				
3.2.P.5.3	Validation of Analytical Procedures				
3.2.P.5.4	Batch analyses				
3.2.P.5.5	Characterisation of Impurities				
3.2.P.5.6	Justification of specification(s)				
3.2.P.6	Reference Standards or Materials				
3.2.P.7	Container Closure System				
3.2.P.8	Stability				
3.2.A	APPENDICES				
3.2.A.1	Facilities and Equipment				
3.2.A.2	Adventitious Agents Safety Evaluation				
3.2.A.3	Excipients				
3.2.R 3.3	REGIONAL INFORMATION				
3.3	LITERATURE REFERENCES				

1. Why?. Registration Procedures

- National
- MRP/DCP
- Centralised Procedure

A medicinal product may only be placed on the market in the EU when a Marketing Authorisation has been issued by: the Same legal requirements irrespective of the competent route/procedure for the authorisations authority granted on the basis of quality, safety and of the Member efficacy. State(s) (MS) Mutual Centralised Decentralised National Recognition or by the Procedure Procedure Procedure Procedure European (CP) (DCP) (NP) (MRP) Commissio n (EC)

1. Why?. National Procedure

• National Health Authorities in each Member State



- Marketing authorisation in a single EU Member State
- Result: National approval national SPC
 - Difference between Member States

1. Why?. Mutual Recognition Procedure (MRP) Decentralized Procedure (DCP)



- If the medicinal product <u>already has</u> a national Marketing Authorisation (MA) in the EU
- Marketing in the countries of the EU included in the MRP




DESCENTRALIZED PROCEDURE (DCP)

- If the MP <u>HAS NOT</u> a previous national MA in the EU
- Marketing in the countries of the EU included in the DCP

1. Why?. Centralized Procedure (CP)




1. Why?. Life-cycle Management



Medicinal Product Lifecycle

1. Why?. Registration Dossier: eCTD & CESP



CESP		
- C B Es seguro ht	tpm://cespportal.hms.eu/dellvary/crasta	* 6
Apticaciones 🛅 API 🛅 SIT	a Agencia Buigaria - 80 🖄 Agencia Augelia - AL 📄 Agencia Augelia - AL 📄 Agencia Buigaria - 80 🐘 Agencia Buigaria - 80 🐘 Agencia Buigaria - 80	
HMA Submissie	European n Portal	
Bashboard	New Delivery File	
New Delivery File		
, Web Upload	The Step 1 Step 2 Step 3 Step 4	
integrated Upload	Conçany *	œ
SFTP Details	- Galericum Haath	
Deliveries		
Support	rees /	
Training	-	
Reports	Regulatory Activity "	0
4 Announcements	- Salect	*
Contacts	Bub Adhity *	۲
General Information	- 3mct	0
	Zo Fie Type *	
? FAQs	- Select	÷
Terms & Conditions	Convent	0
		Next >

÷

÷


÷

÷

÷

1. Why?. Registration Dossier: eCTD & CESP

- Since January 2017 All submissions in CP and new MAA in DCP and MRP (human) in eCTD
- From Q3 2018 All new MAA in NP (human) in eCTD



1. Why?. Legal Basis

• Article 8(3) Full Application

- Full dossier; quality, nonclinical and clinical data

• Article 10 (1) Generic

- Reference product on the market no less than 8 years
- Same qualitative, quantitative compositions
- Same pharmaceutical form
- Bioequivalence

Article 10 (3) Hybrid (mixed) Application

- Additional non-clinical/clinical data in case:
 - Product does not meet definition of generic
 - No bioequivalence
 - in case of changes in the active substance(s),
 - Change to active substance, therapeutic indications, strength, pharmaceutial form or route of administration

Article 10(a) Well established use

- Well-established medicinal use of active substance for at least 10 years
- Non-clinical and clinical trial results replaced by appropriate scientific literature


• Article 10(b) Fixed combination products

- Active substances used in composition of authorised medicinal products but not in combination
- New non-clinical and clinical data relating to the combination are required

1. Why?

RA is involved in the whole product's life:

- from initial development, including clinical trials.
- obtaining MAs, while ensuring it meets corresponding regulations,
- to actually writing the product information, price & reimbursement, advertising materials...
- The "go-between" the company and the corresponding Health Authority, to ensure that their medicinal products meet all the necessary regulations
- RA requires scientific, legal and business knowledge



2. One day in the office

• One day in the office:



emails, meetings, deficiency letters, deadlines, doubts, variations, New initial MA submission, prices, Compilation of dossier, interdepartmental queries, advertising materials search for updated legislation...

2. One day in the office

Best of the job position

- Compilation of a registration dossier
- Getting the approval of a MA or a difficult variation

Worse of the job position


- Administrative work
- Product Information (SmPC, PL and outer labelling)

Interdepartmental relations

- Provide support to all departments in the company: Supply Chain, Quality Assurance, Finance, Commercial, R&D...

What you have to lead with?

- Strick deadlines.
- Work under pressure.
- Liaising and negotiating with regulatory authorities and colleagues



Why?

One day in office

What is the market looking for

Are you the person?

Career Development

3. What is the market looking for?

• Career:

- Relevant Degree in Health Science, preferably Pharmacy (Chemistry, Biochemistry, biotechnology, Medicine, etc)
- Normally, post-graduate focused in Industry required, including internship. Ex: CESIF, UB, etc.
- High English level

• Skills:

- Organised, responsible...
- Attitude: easy learning, multi-task, focused ...
- Negotiation, analytical & communication skills.
- Time management, problem solving...
- Understanding of relevant legal, scientific, manufacturing...

RA Intership



- · Valorable Master en Regulatory Affairs.
- . Inglés nivel B2 (First Certificate), demostrable buen nivel oral.
- · Pensamiento analítico y afinidad con Aplicaciones informáticas.

RA officer

Descripción

Purpose of the role:


We are looking for a Regulatory Affairs Officer CMC with experience within pharmaceutical industry to join our team in our Madrid Office. Someone who loves to take new challenges, to work in an international environment and who wants to grow with us.

Regulatory Affairs Officer main responsibilities:

Overall management of Regulatory Activities in different regions and procedures worldwide (EU, US, RoW):

- New registrations
- Life-cycle management
- · Support in CMC / quality
- · Regulatory strategy and assessment in development
- Authoring of regulatory documentation
- Critical revision of regulatory documentation
- Responsible person for specific client
- Responsible person for communication with authorities
- Responsible for achieving deadlines and overall quality of the work to ensure the best client satisfaction
- Preparation of team-related trainings both internal and external
- Support in business development and marketing activities
- Establish processes and work instructions

According to the project the applicable activities can be done for medicinal products, medical devices, cosmetics, biocides, and other regulated products



Why?

One day in office

What is the market looking for

Are you the person?

Career Development

- RA requires scientific, legal and business knowledge
- Typical employers of regulatory affairs departments are:
 - Relevant Degree in Health Science, preferably Pharmacy (Chemistry, Biochemistry, biotechnology, Medicine, etc
 - Normally, post-graduate focused in Industry required, including internship. Ex: CESIF, UB, et
 - High English level

RA Junior Specialist - Job description

- Compilation, evaluation and submission of complete registration dossiers to local and international regulatory agencies, of Galenicum developed products and licensing from other companies; under other RA team senior associate supervision
- Monitoring, updating and adapting documents, preparing submissions of license variations and renewals;
 under other RA team senior associate supervision
- Management of documentation and requirements for providing 3° APIs to customers
- Pricing and reimbursement
- Maintenance of approved dossiers and RA internal databases


RA Senior Specialist - Job Description

- Compilation, evaluation Providing advice about corresponding regulations to other departments of the company. Compilation, evaluation and submission of complete registration dossiers to local and international regulatory agencies, of Galenicum developed products and licensing from other companies
- Monitoring, updating and adapting documents, preparing submissions of license variations and renewals
- Support in developing and writing clear arguments and rationale according to Health Authorities' requests
- Proactively taking part in internal regulatory strategies
- Auditing 3° part registration dossiers and DMFs
- Conducting Regulatory Affairs related trainings courses
- Management of documentation and requirements for providing 3° APIs to customers
- Maintenance of approved dossiers and RA internal databases

• All RA specialist – Job Description

- Ensuring compliance with regulations set by corresponding Health Authorities, as applicable
- Keeping up to date with changes in applicable regulatory legislation and guidelines
- Liaising and negotiating with applicable regulatory authorities





Why?

One day in office

What is the market looking for

Are you the person?

Career Development

5. Career development

Future opportunities

- RA senior role, progressing to regulatory coordinator, manager, head....

• Develop your career into a another area: QA, clinical, PM...

• Knowledge development in different areas:

- Human medicinal products
 - Generic medicinal products
 - Innovative medicinal products
 - Veterinarian medicinal products
 - Medical devices.
 - Cosmetics
 - Food supplements
 - Etc...
- Not only RA -EU:
 - FDA USA.
 - Canada, Australia, NZ...
 - LATAM
 - Brasil.
 - MENA
 - Etc..


5. Career development

• Expected salary for junior/senior positions

TÉCNICAS	REMUNERACIÓN EN EUROS		BONUS %
PUESTO / EXPERIENCIA	MIN	MAX	BON
Técnico/Responsible QC	24.000€	55.000€	0-5
Técnico/Responsible QA	26.000€	60.000€	0-5
Dirección Técnica	38.000€	85.000€	5-10
Técnico/Responsible Regulatory	28.000€	85.000€	5-15
Técnico/Dirección I+D	24.000€	90.000€	10-30

Thank you





1



xxx@galenicum.com

1. What is a Marketing Authorisation (MA)?

- **a.** A license to sell a medicine.
- **b.** A license granted by "Competent Authorities".
- C. A license issued after the evaluation of the registration dossier.
- d. All above are correct.

2. The assessment for the approval of a medicinal product is based on?

- **a.** The quality, safety and price of the medicinal product.
- **b.** The quality, safety and efficacy of the medicinal product.
- **C.** The quality, efficacy and marketing of the medicinal product.
- d. All above are correct.